ArticleJournal of veterinary internal medicine2026
A treatment monitoring protocol to determine clinical remission in dogs with pulmonary coccidioidomycosis.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPulmonary coccidioidomycosis (PC) is a common cause of respiratory tract disease in dogs from endemic regions, but evidence-based guidelines for monitoring treatment and determining remission are lacking. HYPOTHESIS/
objectivesDescribe temporal changes in clinical signs, antibody serology, and thoracic radiographs in dogs with PC, and evaluate the performance of a treatment monitoring protocol to determine clinical remission. ANIMALS: Thirty-one client-owned dogs with newly diagnosed PC.
methodsA prospective, cohort study. Dogs were examined at diagnosis (T0) and once every 3 months (T1-T4) until remission or for a maximum of 12 months. Clinical status was assessed using an owner-completed visual analog scale (VAS) representative of the 24 hours and 7 days that preceded the visit.
resultsThe 24-hour and 7-day VAS scores increased (ie, clinical signs improved) from T0 (24-hour: mean, 95% confidence interval [CI]; 42.3 mm, 35.0-50.2; 7-day: 39.6 mm, 31.9-47.3) to T1 (24-hour, 85.7 mm, 78.1-93.3, 7-day, 84.4 mm, 76.8-92.1, P < .001) with minimal change thereafter. Immunoglobulin G titers decreased from T0 (median, interquartile range [IQR]; 1:16, 1:4-1:32) to T1 (1:2, 1:1-1:8, P < .001) without significant changes thereafter. Eighty-four percent (26/31) of dogs achieved remission in a mean of 258.9 days (SD, 108.9), which occurred at T1 (13%, 4/31), T2 (23%, 7/31), T3 (32%, 10/31), and T4 (16%, 5/31). Relapse occurred in 15% (4/26) of dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Most dogs with PC are expected to achieve remission within 6-9 months of starting antifungal treatment, and relapse is not uncommon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.